Effects of Siponimod on Mice T Cells and Central Nervous System
In a study with mice, siponimod treatment led to significant T cell lymphopenia, decreasing CD8+ T cell counts while increasing double-negative and CD4+CD25+ T cells. The drug was found to penetrate the central nervous system effectively, with higher concentrations in the hippocampus than in plasma. However, it did not impact oligodendrocyte lineage cells, microglial cells, or any behaviors in the mice.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet tested in people
- Mechanism
- Not reported
- Evidence strength
- Early – laboratory or animal research
- Outcome
- Not reported
Results in cells or animals often do not carry over to people with MS.
Why it matters
These findings are important as they show siponimod's immunomodulatory capabilities and its ability to cross the blood-brain barrier, which could have implications for treating conditions like multiple sclerosis.
What this does not prove
The study indicates that siponimod does not exert direct effects on glial cells or behavior, focusing primarily on immune system modulation in normal physiological conditions.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-30
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceSiponimod Induces Peripheral T Cell Redistribution Without Affecting Glial Cells or Behavior in Naïve Mice. ↗DOI: 10.3390/brainsci16101060
Supporting passages (9)
study phasePublication date: 2026-09-30
subjectsWe investigated the systemic and central effects of siponimod in naïve mice treated orally with 3 mg/kg for 19 consecutive days.
speciesWe investigated the systemic and central effects of siponimod in naïve mice treated orally with 3 mg/kg for 19 consecutive days.
peer reviewedPublication types: Journal Article
publication datePublication date: 2026-09-30
interventionSiponimod treatment induced pronounced T cell lymphopenia, characterized by reduced CD8+ T cells and increased proportions of double-negative T cells and CD4+CD25+ T cells.
findingsSiponimod treatment induced pronounced T cell lymphopenia, characterized by reduced CD8+ T cells and increased proportions of double-negative T cells and CD4+CD25+ T cells.
limitationsConclusions: Taken together, these findings demonstrate that under physiological conditions, the actions of siponimod lie primarily in its immunomodulatory effects, while direct effects on glial cells and behavior are absent.
human efficacyWe investigated the systemic and central effects of siponimod in naïve mice treated orally with 3 mg/kg for 19 consecutive days.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.